Article

Role of laparoscopic surgery in the management of endometrial cancer.

Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190, USA.
Journal of the National Comprehensive Cancer Network: JNCCN (Impact Factor: 4.24). 06/2009; 7(5):559-67.
Source: PubMed

ABSTRACT Minimum surgical treatment for endometrial cancer is removal of the uterus. The operative approach to achieve that goal ranges from vaginal hysterectomy alone to laparotomy with radical hysterectomy, bilateral salpingoophorectomy, bilateral pelvic and para-aortic lymphadenectomy with possible omentectomy, and resection of all metastatic disease. Stratifying the risk factors for predicting presence of metastatic disease has error rates exceeding tolerance for many gynecologic oncologists. Most accept routine laparoscopic surgical staging with hysterectomy, pelvic and para-aortic lymphadenectomy, and removal of adnexa as standard care for patients with endometrial cancer. Modifying the extent of surgical staging for low-risk intrauterine findings or excessive risk for postoperative morbidity is also accepted. Laparoscopic surgery has become the ideal initial surgical approach for this disease, allowing for visual inspection of common metastatic sites, biopsy of abnormal areas, and cytology from peritoneal surfaces. The extent of staging can be altered depending on frozen section findings from the uterus, adnexa, and peritoneal surfaces. Intraoperative medical decision-making can be individualized, encompassing all known risk factors for metastases and balancing comorbidities and potential adverse outcomes. This article documents how laparoscopic surgery satisfies the needs of individual patients and surgeons treating this disease.

0 Followers
 · 
41 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Endometrial cancer is the most common form of gynaecological cancer. Laparotomy has traditionally been the surgical treatment of choice, but the laparoscopic approach is gaining wider acceptance by gynaecologic surgeons, and an abundance of clinical information is currently available on all aspects of this approach. Whether in combination with laparoscopic-assisted vaginal or total laparoscopic hysterectomy, laparoscopic staging, including salpingo-oophorectomy and regional lymph-node dissection, is a major component of the treatment of patients with early endometrial cancer. This review examines the various options to treating endometrial cancer and proposes that laparoscopically assisted surgical staging of endometrial cancer is both a feasible and safe option. Comparative analyses of survival and recurrence rates for patients treated by laparoscopy and laparotomy have shown similar survival results. It remains to be proven if these laparoscopic techniques are associated with greater benefits.
    Gynecological Surgery 11/2006; 3(4):245-252. DOI:10.1007/s10397-006-0223-z
  • [Show abstract] [Hide abstract]
    ABSTRACT: While abdominal hysterectomy with bilateral salpingo-oophorectomy and pelvic and paraaortic lymphadenectomy is still considered the gold standard for the surgical treatment of endometrial cancer, the laparoscopic-assisted vaginal hysterectomy (LAVH) plus laparoscopic lymphadenectomy has been performed in FIGO stage I endometrial cancer in selected centers for about a decade. Clinical studies have shown that the frequency of intra- and postoperative complications, the pelvic and paraaortic lymph node yield, and—more importantly—the overall survival, are similar both with the laparoscopic-assisted vaginal approach and the abdominal approach in stage I disease. Blood loss and duration of hospital stay may even be reduced with the LAVH. In summary, provided there is compliance with established oncologic guidelines, LAVH with pelvic and paraaortic lymphadenectomy can probably be performed in patients with endometrial cancer FIGO stage I without safety loss.
    Gynecological Surgery 01/2007; 4(1):3-7. DOI:10.1007/s10397-006-0222-0
  • [Show abstract] [Hide abstract]
    ABSTRACT: Endometrial cancer is a relatively common gynecological cancer which is increasing in incidence. Survival rates are generally good for those with early disease but a significant minority of women have high risk or advanced disease. Better treatments are required to improve outcomes for these women. There is increasing interest in the use of chemotherapy and improved understanding of the molecular biology of endometrial tumours may pave the way for the use of therapeutic biologic agents that target specific molecular pathways. Recent years have seen greater emphasis on an evidence-based approach to the management of women with endometrial cancer. Extended surgery and adjuvant therapy are now used selectively after individual risk assessment for each woman and there is increased interest in the use of chemotherapeutic agents in the adjuvant setting. This review addresses the modern management of endometrial cancer in the light of available evidence and highlights areas of controversy.
    Oncology Reviews 09/2007; 1(2):103-119. DOI:10.1007/s12156-007-0012-6